Skip to main content

Year: 2023

Form 8.3 – Molten Ventures PLC

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree MOLTEN VENTURES PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position...

Continue reading

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of GTB-3650, a 2nd generation nanobody TriKE® for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). “Today’s announcement is an important milestone for GT Biopharma, and we look forward to advancing GTB-3650 for treatment of CD33+ leukemia. We are excited to expeditiously move this molecule into the clinic as we execute...

Continue reading

CareCloud Welcomes Justin Pierce as Chief Sales Officer

SOMERSET, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced the appointment of Justin Pierce as its new chief sales officer (CSO). In this role, Pierce will be responsible for driving sustainable revenue growth and enhancing CareCloud’s position in the rapidly evolving healthcare landscape. Pierce brings more than two decades of experience in the healthcare technology and services industry, having held leadership positions at Azalea Health, abeo, and Ventra Health. Throughout his career, he has consistently demonstrated his ability to forge strong relationships with physician group leaders, hospital executives, and healthcare business professionals, helping them address their...

Continue reading

DayDayCook Announces Share Repurchase Program

Program authorizes up to 500,000 Class A Ordinary Shares to be repurchased NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) — DDC Enterprise Ltd, (NYSEAM: DDC) (“DayDayCook” or the “Company”), a leading content-driven food consumer brand, today announces that its Board of Directors approved a 10b-18 share repurchase program with authorization to purchase up to 500,000 of the Company’s Class A Ordinary Shares. This plan is effective immediately for up to a one-year period. “Following our initial public offering, we remain dedicated to prudent allocation of capital focused on long-term growth opportunities. We believe this share repurchase reflects the Board’s and Management’s confidence in our business, as well as the value we place on shareholder equity,” said DayDayCook CEO Norma Chu. The Company may repurchase Class A Ordinary Shares...

Continue reading

AB Linas Agro Group: notification on acquisition of block of shares of the Company

AB Linas Agro Group, ISIN code LT0000128092 (hereinafter – the Company), received a notification from UAB “SB Asset Management” on the acquisition of block of shares and voting rights of the Company (enclosed).Additional information: Mažvydas Šileika, Finance Director of AB Linas Agro Group Mob. +370 619 19 403 E-mail m.sileika@linasagro.ltAttachmentNotification-of-aquisition-of-block-of-shares LNA-s1204

Continue reading

Mullen Automotive Hires Basile Law Firm P.C. to Review Prior Financings and Provide Strategic Review of Future Funding Initiatives

Law firm engaged to assist the Company in reviewing its current fundings and to make recommendations in developing its floorplan for 2024 fundings BREA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that it has hired Mark R. Basile, Esq. and his law firm, The Basile Law Firm P.C., to assist the Company in reviewing its current fundings and to make recommendations in developing its floorplan for future fundings. “Mullen is committed to full transparency to the public markets. We are making this announcement in an effort to notify our shareholders that we fully intend to take any and all measures necessary to continue our sustainable growth as we move ahead with previously announced strategic...

Continue reading

Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million

Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the sale of the SofPulse® business and medical Intellectual Property (IP) to SofPulse, Inc.. ENDV is expected to receive the greater of $50 million or a price to be determined by a qualified third party’s asset valuation acceptable to the Endonovo board. It was further agreed, that SofPulse, Inc. will prepare to fulfill the regulatory requirements for a NASDAQ listing following the sale’s completion. To fuel SofPulse, Inc. operations, the company aims to conduct a capital raise of up to $500,000 through a 506 offering tailored for...

Continue reading

TMT Acquisition Corp Announces Entering into a Merger Agreement with eLong Power, a Specialty Battery Technologies Provider for Applications in Commercial EV and Energy Storage

Transaction anticipated to close in the first half of 2024 NEW YORK, N.Y. and Ganzhou, China, Dec. 04, 2023 (GLOBE NEWSWIRE) — TMT Acquisition Corp (“TMTC”) (NASDAQ: TMTCU), a publicly traded special purpose acquisition company (SPAC), and eLong Power Holding Limited (“eLong Power”), a provider of high power battery technologies for commercial and specialty vehicles and energy storage systems, today announced that they have entered into a definitive business combination agreement, dated December 1, 2023, that will result in eLong Power becoming a publicly traded company. Huizhou Yipeng Energy Technology Co., Ltd. (“Yipeng Huizhou”, together with eLong Power, the “Company”) is the operating entity of eLong Power. Upon the closing of the transaction, the combined company is expected to be named eLong Power Inc. and its securities...

Continue reading

LKQ Corporation Announces New Leadership Appointments

John Meyne appointed Senior Vice President of LKQ and President of its Wholesale – North America segmentAndy Hamilton appointed Senior Vice President of LKQ and President of its European segmentCHICAGO, Dec. 04, 2023 (GLOBE NEWSWIRE) — LKQ Corporation (Nasdaq: LKQ) previously announced that Justin Jude, the Company’s current Senior Vice President and President of its Wholesale – North America segment, has been appointed to serve as LKQ’s Executive Vice President and Chief Operating Officer from January 1, 2024 until he officially succeeds Dominick Zarcone as President and Chief Executive Officer of LKQ on July 1, 2024. Today, the Company is announcing two additional leadership appointments. First, the Company’s Board of Directors (the “Board”) has appointed John Meyne, currently the East Division Vice President of LKQ’s Wholesale – North...

Continue reading

Pharmaceutical Excipients Market Size Worth USD 10.43 Billion in 2032 | Emergen Research

Rising demand for functional excipients and oral pharmaceutical medicines and increasing number of pharmaceuticals industries across the globe are key factors driving Pharmaceutical Excipients market revenue growth. Vancouver, Dec. 04, 2023 (GLOBE NEWSWIRE) — The global pharmaceutical excipients market size was USD 6.00 Billion in 2022 and is expected to register a rapid revenue CAGR of 5.7% during the forecast period. The global pharmaceutical excipients market is experiencing substantial growth, primarily fueled by the rising demand for functional excipients and oral pharmaceutical medicines worldwide. The market is also driven by the expansion of pharmaceutical industries and an increasing preference for generic medications. Pharmaceutical excipients, inert chemicals integral to drug manufacturing, play a pivotal role in enhancing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.